Regeneron Names New VP, Quality Assurance and Regulatory Affairs

Regeneron Pharmaceuticals, Inc. (Tarrytown, N.Y.) has appointed Stephen L. Holst as vice president, quality assurance and regulatory affairs.

From 1993 until his appointment by Regeneron, Mr. Holst was employed by Novo Nordisk A/S as vice president of regulatory and quality of the biopharmaceuticals division and subsequently as senior regulatory officer and responsible head of the Worldwide Health Care group. From 1990 to 1993, Mr. Holst was director of Regeneron's regulatory affairs and quality assurance groups.

Mr. Holst said, "I was originally attracted to Regeneron in 1990 by the presence of a group of extremely talented scientists and an important drug candidate. Regeneron now again has several product opportunities in or moving toward the clinic, such as brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), and AXOKINEd, and a significant research and development program. This is an excellent time for me to rejoin the Company to assist in moving products rapidly and efficiently through the regulatory process and, if successful, to the patient."

Commented Leonard S. Schleifer, M.D., Ph.D., president and CEO of Regeneron, "We are pleased that Steve has rejoined Regeneron. The Company is expanding its development capabilities; we're bringing several product candidates forward from the laboratories into the clinic. I am confident that Steve's knowledge and experience will provide important contributions to our efforts."